{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-329000","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2021-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.578261+00:00","generated_at":"2026-06-28T08:27:50.993582+00:00","sec_items":["1.02","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"UroGen Q3 Jelmyto rev $11.4M; ends Allergan pact; shifts UGN-102 trial to single-arm Phase 3","bullets":["Q3 2021 net product revenue $11.4M; net loss $30.2M ($1.35/share) vs $28.8M loss ($1.31) in Q3 2020.","Full-year 2021 revenue guidance $47-51M; operating expense guidance reduced to $137-142M from $155-165M.","Ceased enrollment in ATLAS Phase 3 for UGN-102; new single-arm Phase 3 trial planned for early 2022; NDA submission expected 2024.","Mutually terminated license agreement with Allergan effective November 11, 2021.","Cash and equivalents $110.3M as of Sep 30; Jelmyto site activations up 73% since August 1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-329000","json":"https://secwatch.observer/filing/0001193125-21-329000.json","markdown":"https://secwatch.observer/filing/0001193125-21-329000.md","text":"https://secwatch.observer/filing/0001193125-21-329000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312521329000/0001193125-21-329000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312521329000/d243248d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T08:27:50.993582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}